-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

Benzinga·10/05/2026 20:16:45
Listen to the news
Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.